Public healthcare companies specializing in biotechnology, life science tools, diagnostics, and medical technology will meet with institutional investors at the 5th annual ROTH Healthcare Opportunities Conference. Hosted by ROTH Capital Partners, the event is scheduled for Sept. 29 at The Metropolitan Club in New York City.
B2i Digital, Inc. is serving as the marketing partner for the conference, providing digital marketing, media network support, and social media services. The program is designed to facilitate direct interaction through 25-minute one-on-one and small group meetings. These sessions, which run from 8 a.m. to 4:30 p.m., are intended to place institutional clients in front of C-level executives from various public healthcare sectors.
A series of themed panels will complement the private meetings. The Frontiers in Neuroscience panel will feature representatives from Annovis Bio, CervoMed, Gain Therapeutics, MediciNova, and ProMIS Neurosciences. Additionally, Dr. Frank Lichtenberg, professor emeritus of healthcare management at Columbia University, is scheduled to speak on the economics of drug value and its impact on pricing and coverage.
Other scheduled discussions include a Biotech Reset panel, which will address regulatory uncertainty, capital constraints, and the search for value. This session will feature Kendall Square Policy Strategies, PolyPid, and Newron Pharmaceuticals. A separate panel will examine the rise of minimal residual disease monitoring in solid tumors, featuring insights from Biodesix, DeciBio, and Memorial Sloan Kettering Cancer Center.
The conference is an invitation-only event, and all registrations are subject to approval by ROTH. Confirmed participants as of late August include a variety of firms such as 908 Devices Inc., Akari Therapeutics Plc, Arcturus Therapeutics Holdings Inc., and several others within the biotech and diagnostics industries.
